Upper GI 2017

Oesophageal Cancer – CROSS Study

Neoadjuvant R-CTX. 41,4 Gy: Carbo AUC2 + Paclitaxel 50mg/m² weekly RESECTION

R A N D O M

N=363

T1N1M0 or T2–3N0–1M0

Primary endpoint: overall survival

AC* SCC**

RESECTION

*AC: Adenocarcinoma **SCC: Squamous cell cancer

Van Hagen et al. N Engl J Med 2012; 366: 2074-2084 Shapiro J et al., Lancet Oncol 2015; 16: 1090–98

© Universitätsmedizin Leipzig: University Cancer Center Leipzig (UCCL), Prof. Dr. F. Lordick